# A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

> **NCT05641493** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 49 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **COMBINATION_PRODUCT:** HLX208+HLX10

## Key facts

- **NCT ID:** NCT05641493
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-28
- **Primary completion:** 2025-03-04
- **Final completion:** 2026-02-27
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2023-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05641493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05641493, "A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05641493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*